Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
GE HEALTHCARE Limited currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. This volume of activity reflects an active prosecution strategy for the company's pharmaceutical and biotech innovations across several specialized fields.
These 5 pending office actions are distributed among a matching number of distinct examiners and 3 distinct art units. This spread indicates that the company's technology is being reviewed by a diverse group of specialists across several different administrative sections of the patent office, each with its own technical focus.
ALDERSON, ANNE-MARIE K is the busiest examiner, currently overseeing 1 pending office action. Since each of the distinct examiners is responsible for only one matter, the company must navigate five different examiner perspectives to advance its portfolio within the 3 distinct art units. Practitioners should be prepared for varying feedback across these different administrative sections while managing the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
| No statute on record | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
| ALDERSON, ANNE-MARIE K | 1 | 33.1% | +41.9% |
| SCHLIENTZ, LEAH H | 1 | 41.8% | +38.7% |
| BRAZIN, JACQUELINE | 1 | 65.6% | +52.7% |
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569180 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | SCHLIENTZ, LEAH H | — |
| 18557528 | ANALYTICAL HPLC | BRAZIN, JACQUELINE | — |
| 17415842 | ULTRASOUND CONTRAST AGENT AND METHODS FOR USE THEREOF | CRAIG, KAILA ANGELIQUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859500 | MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS | ALDERSON, ANNE-MARIE K | 34d |
| 19425391 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | MEJIAS, SAMANTHA LEE | — |
| 18569180 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | SCHLIENTZ, LEAH H | — |
| 18557528 | ANALYTICAL HPLC | BRAZIN, JACQUELINE | — |
| 17415842 | ULTRASOUND CONTRAST AGENT AND METHODS FOR USE THEREOF | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 4 |
| 3682 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19425391 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | MEJIAS, SAMANTHA LEE | 1618 | §103 | Non-Final OA | — | Pending | Dec 18, 2025 |
| 18859500 | MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS | ALDERSON, ANNE-MARIE K | 3682 | §103 | Final Rejection | 34d | Pending | Oct 23, 2024 |
| 18569180 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | SCHLIENTZ, LEAH H | 1618 | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18557528 | ANALYTICAL HPLC | BRAZIN, JACQUELINE | 1798 | §102§103 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18541705 | CHELATE COMPOUNDS | BAEK, JONGHWAN NMN | 1618 | Other | Non-Final OA | — | Pending | Dec 15, 2023 |
| 17415842 | ULTRASOUND CONTRAST AGENT AND METHODS FOR USE THEREOF | CRAIG, KAILA ANGELIQUE | 1618 | §103§112 | Non-Final OA | — | Pending | Jun 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGE HEALTHCARE Limited has 6 pending office actions as of October 2026, spread across 3 art units and 6 examiners.
Samantha Lee Mejias has the most, with 1 of GE HEALTHCARE Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
